Alan V Boddy

6PUBLICATIONS
14CO-AUTHORS
Instruments and techniquesEmergency medicinePharmacogenomicsInfant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Harry J Iland, John Reynolds, Alan V Boddy

|Apr 23, 2022
Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With Imatinib.

Jeffry Adiwidjaja, Josephine A Adattini, Alan V Boddy

|Jan 20, 2022
Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib.

Jeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan

|Sep 18, 2021
Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens.

Jeffry Adiwidjaja, Annette S Gross, Alan V Boddy

|Apr 07, 2020
Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach.

Jeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan

|Sep 28, 2018
Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.

J K Duong, G J Veal, C E Nath

Pageof 1

Frequent Collaborators

4 joint publications

Jeffry Adiwidjaja

4 joint publications

Andrew J McLachlan

1 joint publications

J K Duong

1 joint publications

G J Veal